Home ASH Conference Coverage ASH Focus on CAR-T

ASH Focus on CAR-T

Liso-cel Versus Standard of Care as Second-Line Therapy for Relapsed/Refractory LBCL

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

Tisa-Cel Found Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL

ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma

Axicabtagene Ciloleucel Produces High Complete Response Rates in Large B-Cell Lymphoma

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

CAR T-Cell Therapy Recipients May Have Higher Unplanned Use of Healthcare Resources

BELINDA: Tisa-Cel Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL

Real-World Experience With Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma

Enrollment of Black Americans in Pivotal Chimeric Antigen Receptor-T Cell Clinical Trials

Load more
Subscribe to RSS